Purulent Hydradenitis. Part II
- Authors: Rodionov A.N.1, Sobolev A.V.2, Skrek S.V.1,3, Wolkenstein P.4, Yunovidova A.A.3
-
Affiliations:
- North-Western State Medical University named after I. I. Mechnikov, Ministry of Health of the Russian Federation
- Research Institute of Medical Mycology named after P. N. Kashkin of the North-Western State Medical University named after I. I. Mechnikov, Ministry of Health of the Russian Federation
- The Pierre Wolkenstein French Dermatological Clinic
- Dermatological Service of the Henri Mondor University Hospital
- Issue: Vol 93, No 6 (2017)
- Pages: 41-46
- Section: SHORT COMMUNICATION
- URL: https://medbiosci.ru/0042-4609/article/view/116909
- DOI: https://doi.org/10.25208/0042-4609-2017-93-6-41-46
- ID: 116909
Cite item
Full Text
Abstract
Purulent hydradenitis is a chronic relapsing disease that affects 4% of the population, caused by uncontrolled growth of hair follicle and apocrine gland cells, which leads to the development of autoimmune and then septic inflammation. The provoking factors are obesity, smoking, formation of apocrine glands in the body. The variety of subordinates of Suppurative hydradenitis, differences in the prognosis and course of the disease, as well as the need to manage patients with this pathology in the surgical department, determine the standardization of the therapeutic algorithm and the objectification of the degree of clinical response to the therapy using scoring scales.
Keywords
About the authors
A. N. Rodionov
North-Western State Medical University named after I. I. Mechnikov, Ministry of Health of the Russian Federation
Author for correspondence.
д.м.н., профессор кафедры дерматовенерологии
Russian FederationA. V. Sobolev
Research Institute of Medical Mycology named after P. N. Kashkin of the North-Western State Medical Universitynamed after I. I. Mechnikov, Ministry of Health of the Russian Federation
д.м.н., профессор кафедры
Russian FederationS. V. Skrek
North-Western State Medical University named after I. I. Mechnikov, Ministry of Health of the Russian Federation ;The Pierre Wolkenstein French Dermatological Clinic
к.м.н., ассистент кафедры дерматовенерологии
Russian FederationP. Wolkenstein
Dermatological Service of the Henri Mondor University Hospital
заведующий кафедрой, Дерматологическая служба университетского госпиталя Энри Мондор
FranceA. A. Yunovidova
The Pierre Wolkenstein French Dermatological Clinic
Email: anastasia.yunovidova@gmail.com
врач-дерматовенеролог Клиники кожных болезней Пьера Волькенштейна
Russian Federation
References
- Kurzen H., Kurokawa I., Jemec G. B. et al. What Causes Hidradenitis Suppurativa? Exp. Dermatol. 2008;17(5):455–456.
- Jemec G. B. The Symptomatology of Hidradenitis Suppurativa in Women. Br. J. Dermatol. 1988;119(3):345–350.
- Melnik B. C., Plewig G. Impaired Notch-MKP-1 Signalling in Hidradenitis Suppurativa: an Approach to Pathogenesis by Evidence from Translational Biology. Exp. Dermatol. 2013;22(3):172–177.
- Zouboulis C. C., Desai N., Emtestam L. et al. European S1 Guideline for the Treatment of Hidradenitis Suppurativa/Acne Inversa. J. Eur. Acad. Dermatol. Venereol. 2015;29(4):619–644.
- Canoui-Poitrine F., Le Thuaut A., Revuz J. E. et al. Identification of Three Hidradenitis Suppurativa Phenotypes: Latent Class Analysis of a Cross-Sectional Study. J. Invest. Dermatol. 2013;133(6):1506–1511.
- Poli F., Wolkenstein P., Revuz J. Back and Face Involvement in Hidradenitis Suppurativa. Dermatology. 2010;221(2):137–141.
- Canoui-Poitrine F., Revuz J. E., Wolkenstein P. et al. Clinical Characteristics of a Series of 302 French Patients with Hidradenitis Suppurativa, with an Analysis of Factors Associated with Disease Severity. J. Am. Acad. Dermatol. 2009;61(1):51–57.
- Sartorius K., Lapins J., Emtestam L., Jemec G. B. Suggestions for Uniform Outcome Variables when Reporting Treatment Effects in Hidradenitis Suppurativa. Br. J. Dermatol. 2003;149(1):211–213.
- Freysz M., Jemec G. B., Lipsker D. A Systematic Review of Terms Used to Describe Hidradenitis Suppurativa. Br. J. Dermatol. 2015;173(5):1298–1300.
- Kimball A. B., Kerdel F., Adams D. et al. Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa: a Parallel Randomized Trial. Ann. Intern. Med. 2012;157(12):846–855.
- Grant A., Gonzalez T., Montgomery M. O. et al. Infliximab Therapy for Patients with Moderate to Severe Hidradenitis Suppurativa: a Randomized,
Supplementary files
